SHUTTLE PHARMACEUTICALS HOLDINGS INC (NASDAQ: SHPH)

Company Overview

Shuttle Pharmaceuticals Holdings Inc, founded in 2012 by faculty from Georgetown University Medical Center, is a clinical-stage specialty pharmaceutical company. The firm develops therapies designed to sensitize cancer cells to radiation therapy and protect adjacent normal tissue. Its lead product candidate, Ropidoxuridine, is an orally available halogenated pyrimidine currently in Phase II clinical trials.

Corporate Structure

• Headquarters: Gaithersburg, Maryland
• Employees: 11–50
• Leadership:
  • George Scorsis, appointed Chairman of the Board on May 15, 2025, has over 25 years of executive experience in regulated industries, including biotech and cannabis.
• Major Shareholders:
  • Armistice Capital, LLC and Steven Boyd reported a combined 9.99% ownership in a Schedule 13G/A filing on May 15, 2025.

Recent Developments and News

• October 29, 2024: Priced a $4.5 million at-the-market public offering under Nasdaq rules ($1.525 per share and accompanying warrants).
• March 13, 2025: Closed an underwritten public offering of 19,166,667 shares (or pre-funded warrants) at $0.30 per share, raising approximately $5.75 million.
• May 15, 2025 & May 28, 2025: Filed Form 8-K reports under Items 5.02 and 5.07 detailing changes in directors and executive officers.
• June 2025: Announced a proposed reverse stock split to achieve compliance with Nasdaq’s minimum bid price requirement.
• Clinical Trial Progress: As of May 2025, enrollment in the initial randomized section of the Phase II trial for Ropidoxuridine reached approximately 50%.

Financial and Strategic Analysis

Metric	Value
Share Price (June 12, 2025)	$0.1657 (–25.83% today)
Volume	1,307,718
Market Capitalization	$1.736 million
Enterprise Value	–$954,520
Total Cash (mrq)	$4.51 million
Total Debt/Equity (mrq)	33.61%
TTM Net Income	–$10.47 million
TTM EPS	–2.77
Price/Book (mrq)	0.75
Beta (5Y Monthly)	0.41

• Liquidity & Capital: The negative enterprise value indicates financial liabilities exceeding market capitalization, which may impact ongoing funding for Phase II trial expenditures.
• Profitability: The current net loss reflects a focus on research and development; no revenue was reported for the trailing twelve months.
• Strategic Use of Proceeds: Offering proceeds are intended for clinical trials, marketing, and general corporate purposes.
• Nasdaq Compliance: The proposed reverse split aims to restore compliance with the $1.00 minimum bid price rule.

Market Position and Industry Context

• Sector: Healthcare – Drug Manufacturers (Major)
• Focus Area: Radiation sensitizers and theranostic diagnostics for oncology.
• Competitive Landscape: Operates among clinical-stage biotechs targeting enhanced cancer treatment efficacy; a beta of 0.41 indicates lower sensitivity to market fluctuations.
• Pipeline Diversity: One Phase II candidate (Ropidoxuridine) and three preclinical HDAC inhibitors, in addition to developing diagnostic biomarkers for prostate cancer.

tl;dr

• SHPH shares fell 25.8% to $0.1657 on June 12, 2025, with a trading volume of 1.3 million shares.
• As of March 13, 2025, the company raised $5.75 million in an underwritten offering at $0.30 per share.
• Proposed reverse stock split announced in June 2025 to meet Nasdaq’s $1.00 bid requirement.
• Phase II trial enrollment for Ropidoxuridine reached approximately 50% as of May 2025.
• Armistice Capital filed a 9.99% stake on May 15, 2025; leadership changes were reported in 8-K filings on May 15 and May 28, 2025.